387 related articles for article (PubMed ID: 16328668)
21. Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma.
Nozato M; Kaneko S; Nakagawara A; Komuro H
Int J Oncol; 2013 Jan; 42(1):134-40. PubMed ID: 23135478
[TBL] [Abstract][Full Text] [Related]
22. Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene.
Wang TS; Ding QQ; Guo RH; Shen H; Sun J; Lu KH; You SH; Ge HM; Shu YQ; Liu P
Biomed Pharmacother; 2010 May; 64(5):333-8. PubMed ID: 19914791
[TBL] [Abstract][Full Text] [Related]
23. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
[TBL] [Abstract][Full Text] [Related]
24. The clinical effect of the inhibitor of apopotosis protein livin in melanoma.
Lazar I; Perlman R; Lotem M; Peretz T; Ben-Yehuda D; Kadouri L
Oncology; 2012; 82(4):197-204. PubMed ID: 22441029
[TBL] [Abstract][Full Text] [Related]
25. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
26. Regulation of MYCN expression in human neuroblastoma cells.
Jacobs JF; van Bokhoven H; van Leeuwen FN; Hulsbergen-van de Kaa CA; de Vries IJ; Adema GJ; Hoogerbrugge PM; de Brouwer AP
BMC Cancer; 2009 Jul; 9():239. PubMed ID: 19615087
[TBL] [Abstract][Full Text] [Related]
27. Livin may serve as a marker for prognosis of bladder cancer relapse and a target of bladder cancer treatment.
Liu HB; Kong CZ; Zeng Y; Liu XK; Bi JB; Jiang YJ; Han S
Urol Oncol; 2009; 27(3):277-83. PubMed ID: 18555709
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
29. Classification of neuroblastomas based on an analysis of the expression of genes related to prognosis.
Tajiri T; Higashi M; Souzaki R; Tatsuta K; Kinoshita Y; Taguchi T
J Pediatr Surg; 2007 Dec; 42(12):2046-9. PubMed ID: 18082705
[TBL] [Abstract][Full Text] [Related]
30. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer.
Tanabe H; Yagihashi A; Tsuji N; Shijubo Y; Abe S; Watanabe N
Lung Cancer; 2004 Dec; 46(3):299-304. PubMed ID: 15541814
[TBL] [Abstract][Full Text] [Related]
31. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma.
Chen ST; Jeng YM; Chang CC; Chang HH; Huang MC; Juan HF; Hsu CH; Lee H; Liao YF; Lee YL; Hsu WM; Lai HS
Cancer Sci; 2011 Dec; 102(12):2191-8. PubMed ID: 21917080
[TBL] [Abstract][Full Text] [Related]
33. Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma.
Eckerle I; Muth D; Batzler J; Henrich KO; Lutz W; Fischer M; Witt O; Schwab M; Westermann F
Cancer Lett; 2009 Nov; 285(1):99-107. PubMed ID: 19497660
[TBL] [Abstract][Full Text] [Related]
34. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
35. PRAF2 stimulates cell proliferation and migration and predicts poor prognosis in neuroblastoma.
Yco LP; Geerts D; Koster J; Bachmann AS
Int J Oncol; 2013 Apr; 42(4):1408-16. PubMed ID: 23440329
[TBL] [Abstract][Full Text] [Related]
36. Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Am J Pathol; 2003 Mar; 162(3):1019-26. PubMed ID: 12598334
[TBL] [Abstract][Full Text] [Related]
37. Expression of livin in renal cell carcinoma and detection of anti-livin autoantibody in patients.
Kitamura H; Honma I; Torigoe T; Hariu H; Asanuma H; Hirohashi Y; Sato E; Sato N; Tsukamoto T
Urology; 2007 Jul; 70(1):38-42. PubMed ID: 17656204
[TBL] [Abstract][Full Text] [Related]
38. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis.
Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C
Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190
[TBL] [Abstract][Full Text] [Related]
39. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma.
Azuhata T; Scott D; Takamizawa S; Wen J; Davidoff A; Fukuzawa M; Sandler A
J Pediatr Surg; 2001 Dec; 36(12):1785-91. PubMed ID: 11733907
[TBL] [Abstract][Full Text] [Related]
40. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
